Our findings not only suggest that OTUD7B could be a prognostic biomarker for paclitaxel efficacy but also imply that targeting OTUD7B may be a new strategy to enhance the anti-cancer effectiveness of paclitaxel-based chemotherapy against breast cancer, particularly TNBCs. This evidence concerns the gene OTUD7B and breast cancer.